MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Alnylam Pharmaceuticals Cash Conversion Cycle 2011-2026 | ALNY
Annual Cash Conversion Cycle Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46.6 | 55.1 | 57 | 75.6 | 80.5 | 91 | 166 | -7.13 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 166 | -7.13 K | -820 |
Quarterly Cash Conversion Cycle Alnylam Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38 | 36.1 | - | 68.9 | 61.1 | 101 | - | 69.2 | 130 | 176 | - | 97.4 | 36.4 | 91.8 | - | 159 | 101 | 116 | 18.7 | 126 | 146 | 124 | 19 | 133 | 167 | -370 | 24.4 | -23.5 K | 17.2 | 82.6 | 58.5 | 80.2 | 141 | 138 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.88 | -8.33 | -80.7 | - | -287 | -132 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 176 | -23.5 K | -623 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
3.11 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Happiness Biotech Group Limited
HAPP
|
-3.12 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
-101 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
1.73 | - | - | $ 2.17 B | USA |
 |
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
31.4 | - | -34.95 % | $ 21.5 M |  Germany |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 49.98 | -0.5 % | $ 4.49 B |  Schweiz |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
-55.7 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
214 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-3.74 K | $ 31.11 | 3.85 % | $ 2.07 B | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-1.6 K | - | -4.36 % | $ 27 M | USA |
 |
Anika Therapeutics
ANIK
|
192 | $ 14.78 | 0.41 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
-82.3 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-981 | $ 0.68 | -5.31 % | $ 31.1 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.16 | 0.16 % | $ 657 M | USA |
 |
Eton Pharmaceuticals
ETON
|
115 | $ 31.55 | -1.74 % | $ 849 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |